Paul Obrien, MD
Cardiovascular Disease · Annandale, VANPI 1992865588
Payments from drug & device makers
Across 385 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Boehringer Ingelheim$980
- Amgen$828
- Pfizer$591
- Johnson & Johnson$560
- AstraZeneca$507
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,434100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 60 | $1,010 |
| Boehringer Ingelheim | 50 | $980 |
| Amgen | 39 | $828 |
| Pfizer | 29 | $591 |
| Johnson & Johnson | 28 | $560 |
| AstraZeneca | 26 | $507 |
| Merck | 27 | $499 |
| E.r. Squibb & Sons, L.L.C. | 19 | $341 |
| Esperion Therapeutics, Inc. | 15 | $319 |
| Bayer | 14 | $208 |
| Amarin Pharma, Inc. | 10 | $182 |
| Scpharmaceuticals Inc. | 6 | $164 |
| Novo Nordisk | 6 | $153 |
| Sanofi-aventis U.S. LLC | 8 | $143 |
| Atricure, Inc. | 3 | $92 |
| Irhythm Technologies, Inc. | 4 | $88 |
| Regeneron Healthcare Solutions, Inc. | 6 | $86 |
| Actelion Pharmaceuticals US, Inc. | 3 | $83 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $73 |
| Baxter Healthcare | 2 | $67 |
| Boston Scientific | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 2 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Heartflow, Inc. | 2 | $35 |
| Philips North America LLC | 2 | $33 |
| Bardy Diagnostics, Inc. | 2 | $33 |
| Medtronic | 2 | $31 |
| Edwards Lifesciences | 2 | $30 |
| Medicomp Inc | 1 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Abiomed | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Coala Life Inc | 1 | $17 |
| Cvrx, Inc. | 1 | $16 |
| Infobionic, Inc | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
How this compares
$7,434 in reported general payments places this provider in the 75th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $307,121 |
| EntrestoSacubitril/Valsartan | 138 | $193,246 |
| Repatha SureclickEvolocumab | 141 | $126,281 |
| JardianceEmpagliflozin | 81 | $89,049 |
| FarxigaDapagliflozin Propanediol | 39 | $54,460 |
| XareltoRivaroxaban | 35 | $46,037 |
| Eplerenone | 141 | $11,307 |
| Praluent PenAlirocumab | 11 | $8,924 |
| VascepaIcosapent Ethyl | 13 | $8,382 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 31 | $8,364 |
| Ezetimibe | 265 | $8,356 |
| Metoprolol Succinate | 402 | $7,634 |
| Atorvastatin Calcium | 599 | $7,005 |
| Nebivolol Hcl | 106 | $5,527 |
| Rosuvastatin Calcium | 306 | $5,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $591 | $307,121209 claims |
| NovartisEntresto | $1,010 | $193,246138 claims |
| Boehringer IngelheimJardiance | $980 | $89,04981 claims |
| AstraZenecaFarxiga | $507 | $54,46039 claims |
| Johnson & JohnsonXarelto | $560 | $46,03735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Annandale
- Merdod GhafouriAnnandale$120K
- Tariq HaddadFalls Church$8M
- David LimCharlottesville$6M
- Hamid TaheriManassas$4.9M
- Philip OdonnellWinchester$4.6M
- Antonio AbbateCharlottesville$4M
- George VetrovecRichmond$2.3M
- Henry TranFalls Church$1.6M
- John SchmedtjeRoanoke$1.4M
- Jonathan LindnerCharlottesville$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.